KLK1 Antibody

Basic Research Applications

• What is Kallikrein 1 and why is it a significant research target?

  Kallikrein 1 (KLK1), also known as tissue kallikrein, is a serine protease that generates Lys-bradykinin through specific proteolysis of kininogen-1 . KLK1 belongs to the peptidase S1 family and plays crucial roles in various physiological processes including vasodilation, blood pressure regulation, smooth muscle function, and inflammatory responses . The KLK1 gene is one of fifteen kallikrein subfamily members located in a cluster on chromosome 19q13.33, containing 5 coding exons .

  KLK1's significance in research stems from its involvement in multiple pathophysiological conditions. Studies show KLK1 participates in angiogenesis, tissue repair, and cardiovascular function . KLK1 deficiency in mice results in inability to generate significant levels of kinins in most tissues, leading to cardiovascular abnormalities despite normal blood pressure .

• What applications are KLK1 antibodies most commonly used for?

  KLK1 antibodies are utilized across multiple experimental platforms with varying dilution requirements:

  Application	Recommended Dilutions	Common Sample Types
  Western Blotting	1:50-400	Tissue lysates, recombinant proteins
  Immunohistochemistry (Paraffin)	1:10-100	Human and animal tissue sections
  Immunohistochemistry (Frozen)	1:50-500	Fresh-frozen tissue sections
  Immunocytochemistry	1:50-500	Formalin-fixed cells
  ELISA	1:100-5000	Serum, plasma, cell culture supernatants
  Immunoprecipitation	Variable	Cell lysates, conditioned media

  Different antibodies may show optimal performance in specific applications, with some polyclonal antibodies showing broader cross-reactivity across human, mouse, and rat samples . For Western blotting applications, the observed molecular weight of KLK1 is typically 29 kDa, though some reports indicate detection at 22 kDa .

• How should researchers validate KLK1 antibody specificity for their experimental systems?

  Proper validation of KLK1 antibodies is essential for reliable research outcomes. Recommended validation approaches include:

  • Positive controls: Use recombinant KLK1 protein at known concentrations (5-10 ng range) or samples with established KLK1 expression (pancreatic tissue lysates from rat or mouse are well-documented positive controls)

  • Negative controls: Employ KLK1-knockout models where available, or use KLK1 gene silencing via small interfering RNA approaches as demonstrated in functional studies

  • Blocking peptides: Test immunogen-specific peptide blocking to confirm signal specificity in immunodetection methods

  • Cross-validation: Compare results using multiple KLK1 antibodies targeting different epitopes

  • Functional assays: Measure KLK1 enzymatic activity using colorimetric substrates (e.g., S-2266) alongside antibody-based detection methods

  Research indicates that KLK1 expression can be detected in multiple cell types including CD34 positive cells (30±5%), CD19 positive B lymphocytes (23±7%), and CD3 positive T lymphocytes (10±1%) . Additionally, "non-classic" CD16 positive/CD14 low monocytes show high KLK1 expression (43±5%) .

Advanced Research Applications

• How can KLK1 antibodies be used to investigate kallikrein's role in angiogenesis and vascular repair?

  KLK1 antibodies can provide valuable insights into kallikrein's role in angiogenesis through several methodological approaches:

  • Cell Population Analysis: Flow cytometry with KLK1 antibodies can identify specific proangiogenic cell (PAC) populations expressing KLK1. Research shows approximately 60±19% of PACs express KLK1, and these cells demonstrate both membrane and cytoplasmic localization .

  • Migration and Invasion Assays: After manipulating KLK1 expression (via gene silencing or overexpression), KLK1 antibodies can be used to confirm expression changes before assessing functional outcomes. Studies demonstrate that KLK1 silencing reduces PAC migratory, invasive, and proangiogenic activities, while adenovirus-mediated KLK1 expression enhances these functions .

  • Signaling Pathway Analysis: Western blotting with phospho-specific antibodies in conjunction with KLK1 antibodies can elucidate downstream mechanisms. Research indicates KLK1 effects are mediated by kinin B2 receptor (B2R)-dependent mechanisms involving inducible nitric oxide synthase (iNOS) and metalloproteinase-2 (MMP2) .

  • In vivo Models: KLK1 antibodies can be used to track expression in mouse models of ischemia. Studies show KLK1-knockout mouse bone marrow-derived mononuclear cells (MNCs) demonstrate impaired support of reparative angiogenesis in peripheral ischemia models .

  For optimal results, researchers should combine antibody-based detection with functional readouts such as matrigel tube formation assays and in vivo perfusion measurements using Doppler flowmetry or fluorescent microspheres .

• What methodological approaches should be considered when using KLK1 antibodies to study post-translational modifications?

  When investigating KLK1 post-translational modifications, several methodological considerations are critical:

  • Antibody Selection: Choose antibodies recognizing different KLK1 domains or epitopes, as post-translational modifications may mask certain epitopes. The search results indicate antibodies against specific regions (e.g., middle region of human KLK1 or amino acids 25-262) are available .

  • Sample Preparation: Cell lysis conditions significantly impact protein modification status. Use phosphatase inhibitors for phosphorylation studies and protease inhibitors to prevent degradation.

  • Separation Techniques: Employ 2D gel electrophoresis or Phos-tag SDS-PAGE for separation of differentially modified KLK1 forms.

  • Immunoprecipitation-Mass Spectrometry: Enrich KLK1 using specific antibodies followed by mass spectrometry to identify modifications. This approach has been successfully employed for KLK isoform mapping in cancer studies .

  • Activation Status Analysis: KLK1 exists as both zymogen and active enzyme. Compare antibodies recognizing propeptide regions versus mature forms to determine activation status. Research indicates human KLK1 precursor contains a signal peptide (residues 1-18), a pro-peptide (residues 19-24), and a mature chain (residues 25-262) .

  Research has revealed potential post-transcriptional defects in Type 2 diabetic patients, where KLK1 protein levels were lower in proangiogenic cells despite similar mRNA levels to healthy subjects . This suggests focusing on translational or protein stability mechanisms when studying KLK1 in disease contexts.

• How can researchers effectively use KLK1 antibodies to analyze the kallikrein-kinin system in inflammatory disease models?

  Effective analysis of the kallikrein-kinin system using KLK1 antibodies in inflammatory disease models requires integrated experimental approaches:

  • Tissue-Specific Expression Profiling: Immunohistochemistry with KLK1 antibodies can map expression patterns across affected tissues. Research indicates KLK1 is expressed in multiple inflammation-relevant tissues including kidney, skin, brain, lung, heart, and salivary glands .

  • Cell-Type Identification: Use multi-color immunofluorescence combining KLK1 antibodies with lineage markers to identify cell types expressing KLK1 during inflammation. Studies show distinct expression patterns in monocyte subpopulations that may be relevant to inflammatory responses .

  • Functional Blocking Studies: Apply KLK1 antibodies with blocking capability in cell culture systems to assess functional outcomes before proceeding to genetic models. Inhibitors like kallistatin have demonstrated effects on proangiogenic cell yields, suggesting methodological approaches for function-blocking studies .

  • Genetic Models Combined with Antibody Detection: Use KLK1 knockout mouse models with reintroduction of wild-type or mutant KLK1, followed by antibody-based detection to track expression and localization. This approach has been used to demonstrate that KLK1-knockout mouse bone marrow-derived MNCs were unable to support reparative angiogenesis in peripheral ischemia models .

  • Pathway Interaction Analysis: Combine KLK1 antibodies with detection of downstream effectors (B2R, iNOS, MMP2) to establish signaling hierarchies in inflammatory settings .

  In nephritis models, mesenchymal stem cells (MSCs) transduced with human KLK1 gene have shown therapeutic effects by reducing macrophage and T-lymphocyte infiltration into the kidney through suppression of inflammatory cytokines . This suggests KLK1 antibodies could be valuable tools for tracking therapeutic KLK1 delivery and assessing inflammatory cell responses.

• What approaches should be taken when using KLK1 antibodies to investigate discrepancies between protein expression and enzymatic activity?

  Investigating discrepancies between KLK1 protein expression and enzymatic activity requires multi-faceted approaches:

  • Parallel Detection Methods: Simultaneously measure KLK1 protein levels (via antibody-based methods) and enzymatic activity (using colorimetric substrates like S-2266) . This helps identify samples where protein is present but inactive.

  • Activity-State Specific Antibodies: Where available, use antibodies that selectively recognize active versus inactive KLK1 conformations. The catalytically inactive variant R53H-KLK1 has been used as a control in functional studies and could serve as a model for inactive KLK1 .

  • Inhibitor Studies: Use specific KLK1 inhibitors (like kallistatin) alongside antibody detection to determine if detected KLK1 is functionally inhibited in situ .

  • In-situ Activity Assays: Combine immunofluorescence detection with in-situ zymography to co-localize KLK1 protein with areas of proteolytic activity. This method has been applied to study MMP2 activity in relation to KLK1 function .

  • Recombinant Standards: Include purified recombinant KLK1 with known specific activity as a reference standard in experiments. Some commercial antibodies have been validated against recombinant KLK1 proteins with ≥90-95% purity as determined by SEC-HPLC .

  Research has shown differential regulation of KLK1 at protein versus mRNA levels in type 2 diabetic patients, where PACs showed lower KLK1 protein levels despite similar mRNA levels to healthy subjects . This indicates the importance of measuring both expression and activity when studying KLK1 in disease contexts.

• How can KLK1 antibodies be utilized in gene therapy and cell-based therapeutic research?

  KLK1 antibodies play crucial roles in gene therapy and cell-based therapeutic research through several applications:

  • Transduction Verification: Confirm successful gene delivery using antibodies to detect KLK1 expression in transduced cells. Studies have successfully used this approach with human KLK1 (hKLK1) gene transduction into murine MSCs using a retroviral vector .

  • Transgene Expression Monitoring: Track persistence and level of KLK1 expression in transplanted cells over time. Research has confirmed hKLK1 expression in kidneys after transplantation of hKLK1-MSCs in mouse models .

  • Therapeutic Outcome Correlation: Correlate KLK1 expression levels (detected by antibodies) with therapeutic outcomes such as reduced proteinuria, blood urea nitrogen, and ameliorated renal pathology in nephritis models .

  • Comparative Analysis of Variants: Differentiate between functional and non-functional KLK1 variants in therapeutic applications. Studies show that while adenovirus-mediated KLK1 gene transfer enhanced PAC-associated functions, the catalytically inactive variant R53H-KLK1 was ineffective .

  • Mechanism Studies: Use KLK1 antibodies alongside other markers to elucidate mechanisms of therapeutic effect. Research indicates hKLK1-MSCs reduce macrophage and T-lymphocyte infiltration into the kidney by suppressing inflammatory cytokine expression .

  A key methodological finding shows that hKLK1-transduced MSCs demonstrate increased resistance to oxidative stress-induced apoptosis, suggesting a mechanism for enhanced therapeutic efficacy in inflammatory environments . This highlights the importance of antibody-based viability and apoptosis assays when developing KLK1-based cell therapies.

• What are the methodological considerations for multiplexing KLK1 antibodies with other kallikrein family member antibodies?

  Effective multiplexing of KLK1 antibodies with other kallikrein family member antibodies requires careful technical considerations:

  • Epitope Selection: Choose antibodies targeting unique epitopes within each kallikrein to minimize cross-reactivity. The KLK1 immunogen sequence "SQPWQGSTCLASGWGSI" has been used successfully for antibody development with confirmed specificity .

  • Host Species Diversity: Select primary antibodies raised in different host species to allow simultaneous detection with species-specific secondary antibodies.

  • Cross-Reactivity Testing: Validate antibodies against recombinant kallikreins and in samples with selective kallikrein expression patterns. Antibodies with validated absence of cross-reactivity with other proteins are particularly valuable for multiplexing .

  • Multi-color Immunofluorescence Protocols: Optimize blocking, antibody dilution, and detection parameters for each antibody individually before combining. Sequential rather than simultaneous antibody incubation may reduce background.

  • Data Interpretation Controls: Include samples expressing single kallikreins as controls for multiplexed detection. For example, using lysates from cells transfected with individual KLK constructs can serve as specificity controls .

  Research has employed kallikrein antibodies to determine expression patterns of multiple KLKs (including hK11 and hK13) in serum samples from patients with localized prostate cancer . These studies demonstrated significant decreases in specific KLKs in postoperative serum, highlighting the utility of multiplexed kallikrein detection in clinical research.

• What strategies should be employed when using KLK1 antibodies in pathway analysis to study receptor-protease interactions?

  Investigating receptor-protease interactions involving KLK1 requires specialized approaches:

  • Co-immunoprecipitation Protocols: Use KLK1 antibodies to pull down protein complexes, followed by detection of interacting receptors. Western blotting can then confirm interactions with receptors like B2R, which mediates KLK1 effects through a dependent mechanism involving iNOS and MMP2 .

  • Proximity Ligation Assays: Apply KLK1 antibodies alongside receptor antibodies (like B2R) in proximity ligation assays to visualize direct protein interactions in situ with subcellular resolution.

  • Functional Correlation Studies: Combine antibody-based detection with functional assays after receptor manipulation. Research shows B2R blockade suppresses the enhanced invasive capacity of KLK1-overexpressing PACs .

  • Signaling Pathway Analysis: Use phospho-specific antibodies to track activation of downstream pathways following KLK1-receptor interaction. Studies demonstrate that B2R is normally expressed on Type 2 diabetic PACs but remains uncoupled from downstream signaling, highlighting the importance of functional analysis beyond mere expression .

  • Genetic Complementation Approaches: Employ KLK1 antibodies to confirm expression in rescue experiments. Research shows that while adenovirus-mediated KLK1 alone could not restore Type 2 diabetic PAC invasion capacity, combined KLK1 and B2R expression rescued the diabetic phenotype .

  Experimental designs should account for temporal dynamics, as KLK1-receptor interactions may be transient or context-dependent. The homing of proangiogenic cells involves interactions between proteases like KLK1 and chemotactic factor receptors, suggesting these interactions are critical in directional cell movement and tissue invasion .